Sandoz Asks High Court To Toss Fed. Circ. Allergan Ruling

Law360, New York (January 31, 2014, 5:08 PM EST) -- Sandoz Inc. has called upon the U.S. Supreme Court to reverse a Federal Circuit decision upholding the validity of an Allergan Inc. patent for the glaucoma drug Combigan, arguing the panel inflated the value of “unexpected use” as a defense against obviousness and left much of its appeal unaddressed.

In its petition for a writ of certiorari filed Jan. 22, Sandoz told the high court that while the Federal Circuit correctly struck down one Allergan patent covering the act of mixing two known eye medications into...
To view the full article, register now.